RT Journal Article
SR Electronic
T1 Naloxone Buyers Club: Overlooked Critical Public Health Infrastructure for Preventing Overdose Deaths
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.14.21266221
DO 10.1101/2021.11.14.21266221
A1 Doe-Simkins, Maya
A1 Wheeler, Eliza Jane
A1 Figgatt, Mary C.
A1 Jones, T. Stephen
A1 Bell, Alice
A1 Davidson, Peter J.
A1 Dasgupta, Nabarun
YR 2021
UL http://medrxiv.org/content/early/2021/11/16/2021.11.14.21266221.abstract
AB Background Community-based naloxone distribution is an evidence-based pillar of overdose prevention. Since 2012, the naloxone Buyers Club facilitated purchase of low-cost naloxone by harm reduction and syringe service programs, the primary conduits for reaching people who use drugs. This innovative purchasing and mutual aid network has not been previously described.Methods We analyzed transactional records of naloxone orders (2017-2020, n=965), a survey of current Buyers Club members (2020, n=104), and mutual aid requests (2021, n=86).Results Between 2017 and 2020, annual orders for naloxone increased 2.6-fold. 114 unique harm reduction programs from 40 states placed orders for 3,714,110 vials of 0.4 mg/mL generic naloxone through the Buyers Club. States with most orders were: Arizona (600,000 vials), Illinois (576,800), Minnesota (347,450), California (317,200), North Carolina (315,040). Among programs that ordered naloxone in 2020, 52% (n=32) received no federal funding and ordered half as much as funded programs. During the 2021 shortage, mutual aid redistribution was common, with 80% participating as either a donor or recipient. Among 59 mutual aid requestors, 59% (n=35) were willing to accept expired naloxone; the clear preference was for generic injectable naloxone, 95% (n=56).Conclusions The naloxone Buyers Club is a critical element of overdose prevention infrastructure. Yet, barriers from corporate compliance officers and federal prescription-only status impede access. These barriers can be reduced by FDA removing the prescription requirement for naloxone and government funding for harm reduction programs.Competing Interest StatementDr. Dasgupta is a scientific advisor to the non-profit RADARS System of Denver Health and Hospitals Authority, a political subdivision of the State of Colorado (USA). Dr. Dasgupta does not accept personal compensation from any pharmaceutical company, distributor, or litigant. EJW, MD-S, PJD, AB, TSJ, MCF have no disclosures.Funding StatementRemedy Alliance (https://remedyallianceftp.org/ - previously called OSNN Buyers Club) is an unfunded, non-profit entity. MD-S and EJW have volunteered their time to support the Buyers Club for a decade. No funding was received for preparation of this manuscript. Pfizer and Hikma have no direct financial relationship with the Buyers Club; all contracts are with individual programs. Neither company was aware of this manuscript until after submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the University of North Carolina Office of Human Research Ethics, which determined that it does not constitute human subjects research as defined under federal regulations (#21-2451).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. https://doi.org/10.17615/tyd7-qy88 https://doi.org/10.17615/z548-vp45